Study of lecanemab in early Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with early Alzheimer's disease.
- You are currently receiving treatment with lecanemab (also known as Leqembi) as part of your regular care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who are taking or have taken lecanemab (a medication for Alzheimer's disease). It aims to gather more information about the treatment's effects in real-world settings.
This study tests a new treatment, called X/T, for people with Alzheimer's disease who are already taking lecanemab (Leqembi). The goal is to see if adding X/T is safe and tolerable, and if it might help manage symptoms.
This study collects information from people in Canada who have Alzheimer's disease and are prescribed the drug lecanemab (LEQEMBI). It helps doctors learn more about the drug's safety and effects in real-world use.
This study looks at the long-term effects of the Alzheimer's drug LEQEMBI (lecanemab) in people with mild memory problems or early Alzheimer's. It gathers information from patients who have already been taking the drug for 18 months to see how they are doing.
This study tracks the safety of Leqembi (lecanemab), a treatment for Alzheimer's disease, in people who are already prescribed it in the UK. It helps doctors learn more about how the medicine affects patients in everyday life.
This study tests whether adding a new medicine called lencanizumab to usual Alzheimer's treatments can help people in the early stages of the disease. It aims to see if the combination is safe and effective.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.